- Acquired by GSK (GlaxoSmithKline) on May 29, 2013
- Total Equity Funding
- $20.5M in 1 Round from 2 Investors
- Basel, Basel-Stadt
- Okairos AG is a biopharmaceutical company focused on the discovery and development of genetic T-cell vaccines, including hepatitis C virus.
- Riccardo Cortese, Antonella Folgori, Alfredo Nicosia, Stefano Colloca
- Biopharma, Biotechnology, Medical
Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy.
The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.
Funding Rounds (1) - $20.5MUpdate
Current Team (4)Update
Board Members and Advisors (2)Update
|May 17, 2016||Startup Ticker (Switzerland) - New company of former Okairos founders bags €12 million|
|Nov 2, 2015||PRNewswire UK All - Potential New Vaccine Candidate Aims to Block Transmission of Malaria Parasites|
|Nov 2, 2015||PRNewswire All - Potential New Vaccine Candidate Aims to Block Transmission of Malaria Parasites|
|May 11, 2015||Wired News - One Year Later, Ebola’s Lessons for the Next Big Outbreak|
|Nov 24, 2014||Fierce Biotech - Merck steps into Ebola vaccine race with NewLink rights deal|
|Sep 8, 2014||Fierce Biotech - GlaxoSmithKline's Ebola vaccine aces an animal study amid R&D fervor|
|Aug 28, 2014||Fierce Biotech - The Ebola vaccine game plan takes shape as GSK, agencies hit the gas|
|May 29, 2013||fool.com - GlaxoSmithKline Acquires Okairos for $325 Million (GSK)|
Basel, Basel-Stadt CH 4051